Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.
Jiangsu Hengrui Pharmaceuticals has entered into a license agreement with Braveheart Bio, Inc. for its innovative drug HRS-1893, a selective myosin inhibitor currently in Phase III clinical development for treating obstructive hypertrophic cardiomyopathy. This agreement allows Braveheart Bio to utilize Hengrui’s intellectual property, potentially enhancing Hengrui’s market presence in the cardiology sector and expanding its global reach.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company involved in the development and production of innovative drugs, focusing on areas such as oncology, anesthesiology, and cardiology.
Average Trading Volume: 4,966,317
Current Market Cap: HK$497.5B
Learn more about 1276 stock on TipRanks’ Stock Analysis page.